Clinical Trials Logo

Clinical Trial Summary

The study is a 17-week, single-center, double-blind, parallel-group, randomized placebo controlled trial that will test the efficacy of liraglutide 3.0 mg/d as compared to placebo in reducing the number of binge episodes per week, achieving remission from binge episodes, and in changes in body weight, global BED symptom improvement, cognitive restraint of food intake, dietary disinhibition, perceived hunger, quality of life, and depressed mood at treatment end.


Clinical Trial Description

All applicants will be initially screened by phone and/or electronically to determine whether they potentially meet eligibility criteria. Those who appear to meet eligibility criteria and remain interested in the trial will be scheduled for an in-person interview. The in-person interview will be conducted by a psychologist or Masters' level staff member, who will obtain informed consent and evaluate subjects' behavioral eligibility (i.e., willingness and appropriateness to participate) using structured and semi-structured clinical interviews including: an examination of the applicants' BED symptoms, their mood, suicidality, and other general psychopathology. Participants will also be asked to complete questionnaires assessing eating behavior, demographic characteristics, frequency of specific eating behaviors related to loss of control, risk of substance dependence with the consumption of high fat/sugar foods, alexithymia, night eating syndrome, sleep patterns and quality, and attitudes towards food cravings. Subjects who remain interested and pass this portion of the assessment will proceed to meet with the study physician or nurse practitioner, who will obtain a medical history and conduct a physical examination to determine medical eligibility. Subjects will also have an electrocardiogram (EKG), fasting blood test, and a urine pregnancy test (for females of child bearing age) to confirm eligibility. Upon successful completion of the screening visit, subjects will be asked to eat as they normally would for 2 weeks. Once per week over these two weeks they will receive a brief survey through REDcap to assess their binge eating episodes for eligibility. Subjects who continue to meet eligibility criteria assessed at the screening visit and during the run-in period will be scheduled for a randomization visit at the Center within 3 weeks of their screening. Subjects will be randomly assigned to the two interventions in equal numbers (i.e., 1:1 ratio). The subject's weight, blood pressure, and pulse will then be measured. Following randomization, all subjects will have a medical visit with the study physician or nurse practitioner who will instruct them in the use of liraglutide 3.0 (as described later) and provide the first month's supply of medication. After randomization, subjects will return at week 1 to assess rate of response. Subjects will return for study visits every two weeks thereafter, at weeks 3, 5, 7, 9, 11, 13, 15, and 17. These study visits include a brief medical visit (10-15 minutes) with a physician or nurse practitioner to monitor their response to the medication or any changes in health. Vitals and weight will be taken. Additionally, binge episodes, mood, suicidality, and symptom improvement will be assessed by the psychologist or Masters' level trained study staff. Participants will be asked also to complete questionnaires assessing quality of life, obsessions related to food, and food cravings prior to each treatment visit for the secondary outcomes: In summary, study visits will consist of the medical visit, completion of written surveys, review of structured interviews with the study staff and review of medication adverse events. These visits are expected to last about 30-40 minutes. The study assessments at week 17 will consist of the previously listed procedures and measures in addition to the questionnaires and blood tests conducted at baseline. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03279731
Study type Interventional
Source University of Pennsylvania
Contact
Status Terminated
Phase Phase 3
Start date September 29, 2017
Completion date October 1, 2019

See also
  Status Clinical Trial Phase
Completed NCT04572087 - Ameliorating Cognitive Control in Binge Eating Disorder N/A
Completed NCT03063606 - Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment Phase 2/Phase 3
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Terminated NCT04278755 - Binge Eating & Birth Control Phase 2
Completed NCT02419326 - Uniting Couples In the Treatment of Eating Disorders (UNITE) N/A
Completed NCT00210808 - A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Phase 2/Phase 3
Recruiting NCT05937243 - Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating N/A
Completed NCT04115852 - Interoceptive Nutritional Processing in Healthy Participants and Patients With Binge-Eating-Disorder
Completed NCT03113669 - Project BITE: Binge Intervention Target Effectiveness N/A
Completed NCT04265131 - Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome? N/A
Completed NCT06230107 - The Effects of Nutritional Intervention in Participants With Eating Disorders. N/A
Completed NCT03712748 - Online Imaginal Exposure N/A
Recruiting NCT04076553 - Augmenting Cognitive Behavioral Therapy With Inhibitory Control Training N/A
Not yet recruiting NCT04101032 - eBEfree - an ICT Adaptation of BEfree N/A
Recruiting NCT05911334 - Feasibility of the ROADE Program N/A
Completed NCT03317379 - Evaluation of the Communities of Healing Mentorship/Support Group Program: Assessment of Preliminary Efficacy N/A
Completed NCT02783872 - Emotion Regulation and Binge Eating in Youth With Obesity
Recruiting NCT06050616 - Multimodal Longitudinal and Predictive Modelling to Understand Eating Disorder Development
Active, not recruiting NCT02571387 - MindOb: A 12-month Computerized Mindfulness-based Intervention for Obese Individuals N/A